Standard
Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. / Ravnborg, Mads; Sørensen, Per Soelberg; Andersson, Magnus; Celius, Elisabeth G; Jongen, Peter J; Elovaara, Irina; Bartholomé, Emmanuel; Constantinescu, Cris S; Beer, Karsten; Garde, Ellen; Sperling, Bjørn.
I:
Lancet Neurology, Bind 9, Nr. 7, 01.07.2010, s. 672-80.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Ravnborg, M
, Sørensen, PS, Andersson, M, Celius, EG, Jongen, PJ, Elovaara, I, Bartholomé, E, Constantinescu, CS, Beer, K, Garde, E & Sperling, B 2010, '
Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial',
Lancet Neurology, bind 9, nr. 7, s. 672-80.
https://doi.org/10.1016/S1474-4422(10)70132-0APA
Ravnborg, M.
, Sørensen, P. S., Andersson, M., Celius, E. G., Jongen, P. J., Elovaara, I., Bartholomé, E., Constantinescu, C. S., Beer, K., Garde, E., & Sperling, B. (2010).
Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Lancet Neurology,
9(7), 672-80.
https://doi.org/10.1016/S1474-4422(10)70132-0Vancouver
Ravnborg M
, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I o.a.
Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Lancet Neurology. 2010 jul. 1;9(7):672-80.
https://doi.org/10.1016/S1474-4422(10)70132-0Author
Ravnborg, Mads ; Sørensen, Per Soelberg ; Andersson, Magnus ; Celius, Elisabeth G ; Jongen, Peter J ; Elovaara, Irina ; Bartholomé, Emmanuel ; Constantinescu, Cris S ; Beer, Karsten ; Garde, Ellen ; Sperling, Bjørn. / Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. I: Lancet Neurology. 2010 ; Bind 9, Nr. 7. s. 672-80.
Bibtex
@article{7152a303d4684b2cb1b5dffb730e03d5,
title = "Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial",
abstract = "Interferon beta is commonly used to treat patients with relapsing-remitting multiple sclerosis; however, the treatment is only partially effective in reducing relapses and progression of disability. Corticosteroids are used to treat relapses in patients with multiple sclerosis. We therefore aimed to investigate the combination of cyclic methylprednisolone and interferon beta for the treatment of relapsing-remitting multiple sclerosis.",
author = "Mads Ravnborg and S{\o}rensen, {Per Soelberg} and Magnus Andersson and Celius, {Elisabeth G} and Jongen, {Peter J} and Irina Elovaara and Emmanuel Bartholom{\'e} and Constantinescu, {Cris S} and Karsten Beer and Ellen Garde and Bj{\o}rn Sperling",
note = "Copyright 2010 Elsevier Ltd. All rights reserved.",
year = "2010",
month = jul,
day = "1",
doi = "http://dx.doi.org/10.1016/S1474-4422(10)70132-0",
language = "English",
volume = "9",
pages = "672--80",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "TheLancet Publishing Group",
number = "7",
}
RIS
TY - JOUR
T1 - Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial
AU - Ravnborg, Mads
AU - Sørensen, Per Soelberg
AU - Andersson, Magnus
AU - Celius, Elisabeth G
AU - Jongen, Peter J
AU - Elovaara, Irina
AU - Bartholomé, Emmanuel
AU - Constantinescu, Cris S
AU - Beer, Karsten
AU - Garde, Ellen
AU - Sperling, Bjørn
N1 - Copyright 2010 Elsevier Ltd. All rights reserved.
PY - 2010/7/1
Y1 - 2010/7/1
N2 - Interferon beta is commonly used to treat patients with relapsing-remitting multiple sclerosis; however, the treatment is only partially effective in reducing relapses and progression of disability. Corticosteroids are used to treat relapses in patients with multiple sclerosis. We therefore aimed to investigate the combination of cyclic methylprednisolone and interferon beta for the treatment of relapsing-remitting multiple sclerosis.
AB - Interferon beta is commonly used to treat patients with relapsing-remitting multiple sclerosis; however, the treatment is only partially effective in reducing relapses and progression of disability. Corticosteroids are used to treat relapses in patients with multiple sclerosis. We therefore aimed to investigate the combination of cyclic methylprednisolone and interferon beta for the treatment of relapsing-remitting multiple sclerosis.
U2 - http://dx.doi.org/10.1016/S1474-4422(10)70132-0
DO - http://dx.doi.org/10.1016/S1474-4422(10)70132-0
M3 - Journal article
VL - 9
SP - 672
EP - 680
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 7
ER -
